Clinical trial
Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In…
NCT00150345 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00150345 |
|---|---|
| Title | Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients |
| Official title | Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In High-Risk Neutropenic Patients With Fever And A Positive Panfungal Polymerase Chain Reaction Assay (IDEA Study) |
| Acronym | IDEA |
| Lead sponsor | Pfizer, Industry |
| Collaborators | Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Possible Fungal Infection |
| Intervention type | Drug |
| Interventions | voriconazole (Vfend) |
| Enrollment | 147 |
| Start date | Jan 1, 2005 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Sep 8, 2005 |
| Last update posted | Jan 19, 2012 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: